Siwen Hu-Lieskovan, PhD, MD

Journal Article

1. Muhammad Zaki Hidayatullah Fadlullah, Ching-Nung Lin, Samuel Coleman, Arabella Young, Abdul Rafeh Naqash, Siwen Hu-Lieskovan, Aik Choon Tan (2024). Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials. Oncologist, 29(5), 415-421.
2. Magdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, Natalia Sigal, Li-Chun Cheng, William D Chronister, Shane A Evans, John A Marsiglio, Berit Gibson, Yoko S Derose, Annaleah Larson, Carlos O Medina, Ramji Srinivasan, Matthew H Spitzer, Ngan Nguyen, John R Hyngstrom, Hu-Lieskovan S (2024). Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in checkpoint inhibitor-treated melanoma. J Immunother Cancer.
3. Marsiglio J, McPherson JP, Kovacsovics-Bankowski M, Jeter J, Vaklavas C, Swami U, Grossmann D, Erickson-Wayman A, Soares HP, Kerrigan K, Gibson B, Doherty JA, Hyngstrom J, Hardikar S, Hu-Lieskovan S (2023). A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome. Front Immunol.
4. VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong TG, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas A (2023). Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. . Nature Medicine.
5. Harris LN, Blanke CD, Erba HP, Ford JM, Gray RJ, LeBlanc ML, Hu-Lieskovan S, Litzow MR, Luger SM, Meric-Bernstam F, ODwyer PJ, Othus MKD, Politi K, Shepherd LE, Allegra CJ, Chen HX, Ivy SP, Korde LA, Little RF, McShane LM, Moscow JA, Patton DR, Thurin M, Yee LM, Doroshow JH (2023). The New NCI Precision Medicine Trials. Clin Cancer Res.
6. Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A (2023). Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med, 388(9), 813-823. (Read full article)
7. Yap T, LoRusso PM, Wong DJ, Hu-Lieskovan S, Papadopoulos KP, Holz JB, Grabowska U, Gradinaru C, Leung KM, Marshall S, Reader CS, Russell R, Sainson RCA, Seal CJ, Shepherd CJ, Germaschewski F, Gliddon D, Stern O, Young L, Brewis N, Kayitalire L, Morrow M (2022). A Phase 1 first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1 in patients with advanced cancer and PD-L1 resistance. Clin Cancer Res.
8. Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens FALM, Ros W, Diab A, Spano JP, Rizvi NA, Wasser JS, Angevin E, Ott PA, Forgie A, Yang W, Guo C, Chou J, El-Khoueiry AB (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. J Immunother Cancer, 10(10).
9. Diab A, Hamid O, Thompson JA, Ros W, Eskens FALM, Doi T, Hu-Lieskovan S, Klempner SJ, Ganguly B, Fleener C, Wang X, Joh T, Liao K, Salek-Ardakani S, Taylor CT, Chou J, El-Khoueiry AB (2021). A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. Clin Cancer Res, 28(1), 71-83. (Read full article)
10. Wang X, Haaland B, Hu-Lieskovan S, Colman H, Holmen SL (2021). First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma. Cancer Rep (Hoboken), 4(6), e1419. (Read full article)
11. Hu-Lieskovan S, Braiteh F, Grilley-Olson JE, Wang X, Forgie A, Bonato V, Jacobs IA, Chou J, Johnson ML (2021). Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration. Target Oncol, 16(6), 773-787. (Read full article)
12. Diab A, Hamid O, Thompson J, Ros W, Eskens F, Doi T, Hu-Lieskovan S, Klempner S, Ganguly B, Fleener C, Wang X, Jo T, Liao K, Salek-Ardakani S, Taylor C, Chou J, El-Khoueiry A (2021). A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients With Locally Advanced or Metastatic Cancers. Clin Cancer Res.
13. Pokorny R, McPherson JP, Haaland B, Grossmann KF, Luckett C, Voorhies BN, Sageser DS, Wallentine J, Tolman Z, Hu-Lieskovan S, Swami U (2021). Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma. J Immunother Cancer.
14. Hu-Lieskovan S, Bhaumik S, Dhodapkar K, Grivel JJB, Gupta S, Hanks BA, Janetzki S, Kleen TO, Koguchi Y, Lund AW, Maccalli C, Mahnke YD, Novosiadly RD, Selvan SR, Sims T, Zhao Y, Maecker HT (2020). SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. J Immunother Cancer, 8(2). (Read full article)
15. Poran A, Scherer J, Bushway ME, Besada R, Balogh KN, Wanamaker A, Williams RG, Prabhakara J, Ott PA, Hu-Lieskovan S, Khondker ZS, Gaynor RB, Rooney MS, Srinivasan L (2020). Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. Cell Rep Med, 1(8), 100141. (Read full article)
16. Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L (2020). A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 183(2), 347-362.e24. (Read full article)
17. Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM (2020). Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol, 156(9), 1004-1011. (Read full article)
18. Torrejon DY, Abril-Rodriguez G, Champhekar AS, Tsoi J, Campbell KM, Kalbasi A, Parisi G, Zaretsky JM, Garcia-Diaz A, Puig-Saus C, Cheung-Lau G, Wohlwender T, Krystofinski P, Vega-Crespo A, Lee CM, Mascaro P, Grasso CS, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Ribas A (2020). Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. Cancer Discov, 10(8), 1140-1157. (Read full article)
19. Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A (2022). Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy. Nat Cancer, 1(2), 264. (Read full article)
20. Parisi G, Saco J, Salazar F, Tsoi J, Krystofinski P, Puig Saus C, Zhang R, Zhou J, Cheung-Lau G, Garcia AJ, Grasso CS, Tavar R, Hu-Lieskovan S, Mackay S, Zalevsky J, Bernatchez C, Diab A, Wu A, Comin-Anduix B, Charych DH, Ribas A (Jan 2020). Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nat Commun, 11(1), 660.
21. Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A (2019). PAK4 inhibition improves PD-1 blockade immunotherapy. Nat Cancer, 1(1), 46-58. (Read full article)
22. Abril-Rodriguez G, Torrejon T, Zaretsky J, Nowicki T, Tsoi J, Baselga Carretero I, Medina E, Quist M, Senapedis W, Baloglu E, Cheung-Lau G, Puig-Saus C, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Grasso C, Ribas A (Jan 2020). PAK4 inhibition reverses T cell exclusion in cancer and improves PD-1 blockade immunotherapy. Nat Cancer, 1, 46-58.
23. Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, Ying J, Hyngstrom JR (Nov 2019). Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab. Cancer Med.
24. Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, Wang YC, Di Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu CG, Ribas A, Kohn DB, Witte ON, Yang L (Oct 2019). Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. Cell Stem Cell, 25(4), 542-557.e9.
25. Johnson ML, Braiteh F, Grilley-Olson JE, Chou J, Davda J, Forgie A, Li R, Jacobs I, Kazazi F, Hu-Lieskovan S (May 2019). Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial. JAMA Oncol.
26. Hu-Lieskovan S, Lisberg A, Zaretsky J, Wells D, Han M, Shintaku I, Wolf B, Abarca P, Slamon D, Goldman JW, Dubinett S, Ribas A, Garon EB (May 2019). Tumor characteristics associated with benefit from pembrolizumab in advanced non-small cell lung cancer. Clin Cancer Res.
27. Allen CT, Lee S, Norberg SM, Kovalovsky D, Ye H, Clavijo PE, Hu-Lieskovan S, Schlegel R, Schlom J, Strauss J, Gulley JL, Trepel J, Hinrichs CS (May 2019). Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. J Immunother Cancer, 7(1), 119.
28. Nowicki T, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, Macabali M, Garcilazo IP, Carretero IB, Kalbasi A, Cochran A, Grasso C, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A (Apr 2019). A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination With or Without Ipilimumab. Clin Cancer Res, 25(7), 2096-2108.
29. Bethune MT, Li XH, Yu J, McLaughlin J, Cheng D, Mathis C, Moreno BH, Woods K, Knights AJ, Garcia-Diaz A, Wong S, Hu-Lieskovan S, Puig-Saus C, Cebon J, Ribas A, Yang L, Witte ON, Baltimore D (Oct 2018). Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. Proc Natl Acad Sci U S A.
30. Kugel CH 3rd, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT (Jun 2018). Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. . Clin Cancer Res.
31. Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, Morikawa T, Nosho K, Abril-Rodriguez G, Connolly C, Escuin-Ordinas H, Geybels MS, Grady WM, Hsu L, Hu-Lieskovan S, Huyghe JR, Kim YJ, Krystofinski PE, Leiserson MD, Montoya DJ, Nadel BB, Pellegrini M, Pritchard CC, Puig-Saus C, Quist EH, Raphael BJ, Salipante SJ, Shin DS, Shinbrot E, Shirts B, Shukla S, Stanford JL, Sun W, Tsoi J, Upfill-Brown A, Wheeler DA, Wu CJ, Yu M, Zaidi SH, Zaretsky JM, Gabriel SB, Lander ES, Garraway LA, Hudson TJ, Fuchs CS, Ribas A, Ogino S, Peters U (Mar 2018). Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov.
32. Eroglu Z Zaretsky J Hu-Lieskovan S Kim DW, Algazi A, Johnson D, Liniker E, Kong B, Munhoz R, Rapisuwon S, Chmielowski B, Homet Moreno B, Cherry G, Berent-Maoz B, Comin-Anduix B, Wang X, Tumeh PC, Shintaku IP, Hugo W, Lo RS, Sosman JA, Joseph R, Postow M, Hwu W-J, Messina J, Long G, Ribas A Equal contribution as first authors, Corresponding authors (Jan 2018). High response to PD-1 blockadein desmoplastic melanoma. Nature, 553(7688), 347-350.
33. Tolcher A, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco DW, Di Gravio D, Huang B, Gambhire D, Chen Y, Thall AD, Pathan N, Schmidt EV, Chow LQ (Jun 2017). Phase Ib study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with pembrolizumab in patients with advanced solid tumors. Clin Cancer Res.
34. Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Damoiseaux R, Lo RS, Ribas A (2017). Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep, 19(6), 1189-1201.
35. Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Abril Rodriguez G, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A (Nov 2016). Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov.
36. Homet Moreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, Graeber TG, Comin-Anduix B, Hu-Lieskovan S Ribas A Corresponding Authors (Oct 2016). Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells. Cancer Immunol Res, 4(10), 845-857.
37. Zaretsky JM, Garcia Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Rodriguez GA, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez P, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher T, Lo RS, Ribas A (Sep 2016). Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med, 375(9), 819-29.
38. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS (Mar 2016). Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell, 165(1), 35-44.
39. Homet Moreno B, Mok S, Robert L, Comin-Anduix B, Hu-Lieskovan S, Ribas A (Aug 2015). Combined Treatment with Dabrafenib and Trametinib with Immune-stimulating Antibodies for BRAF Mutant Melanoma. Oncoimmunology, 5(7), e1052212.
40. Mok S, Tsoi J, Koya RC, Hu-Lieskovan S, West BL, Bollag G, Graeber TG, Ribas A (May 2015). Inhibition of CSF-1R Improves Antitumor Efficacy of BRAF Inhibition. BMC Cancer, 15(1), 356.
41. Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Koya KC, Graeber T, Comin-Anduix B, Ribas A (Mar 2015). Improved Antitumor Activity of Immunotherapy with BRAF and MEK inhibitors in BRAFV600E mutant melanoma. Sci Transl Med, 7(279), 279.
42. Hu-Lieskovan S, Vallbohmer D, Zhang W, Yang D, Pohl A, Labonte MJ, Grimminger PP, Hlscher AH, Semrau R, Arnold D, Dellas K, Debucquoy A, Haustermans K, Machiels JP, Sempoux C, Rdel C, Bracko M, Velenik V, Lenz HJ (Aug 2011). EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. . Clin Cancer Res, 17(15), 5161-9.
43. Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, Labonte MJ, Wilson PM, Gordon MA, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ (Jan 2011). A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol, 22(1), 104-9.
44. Zwerner P, Joo J, Warner KL, Christensen L, Hu-Lieskovan S, Triche TJ, May WA (May 2008). The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene, 27(23), 3282-91.
45. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ (Oct 2005). Sequence-specific knockdown of EWS-FLI1 by targeted, non-viral delivery of siRNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer Res, 65(19), 8984-8992.
46. Popielarski SR, Hu-Lieskovan S, French SW, Triche TJ, Davis ME (Aug 2005). A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. In vitro and in vivo uptake results. Bioconjug Chem, 16(5), 1071-80.
47. Hu-Lieskovan S, Zhang J, Schofield DE, Shimada H, Wu L, Triche TJ (Jun 2005). EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing’s family of tumors. Cancer Res, 65(11), 4633-44.
48. Heidel JD, Hu S, Liu XF, Triche TJ, Davis ME (Dec 2004). Lack of interferon response in animals to naked siRNAs. Nat Biotechnol, 22(12), 1579-82.
49. Zhang J, Hu S, Schofield D, Sorensen P, Triche TJ (Sep 2004). Selective usage of D type cyclins by Ewing's tumors and rhabdomyosarcomas. Oncogene, 64(17), 6026-34.

Review

1. Sankar K, Ye JC, Li Z, Zheng L, Song W, Hu-Lieskovan S (2022). The role of biomarkers in personalized immunotherapy. [Review]. Biomark Res, 10(1), 32. (Read full article)
2. Yuan J, Khilnani A, Brody J, Andtbacka RHI, Hu-Lieskovan S, Luke JJ, Diab A, Marabelle A, Snyder A, Cao ZA, Hodi FS (2021). Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition. [Review]. Eur J Cancer, 157, 493-510. (Read full article)
3. Okwundu N, Grossman D, Hu-Lieskovan S, Grossmann KF, Swami U (2020). The dark side of immunotherapy. [Review]. Ann Transl Med, 9(12), 1041. (Read full article)
4. Hu-Lieskovan S, Malouf GG, Jacobs I, Chou J, Liu L, Johnson ML (2021). Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need. [Review]. Future Oncol, 17(11), 1401-1439. (Read full article)
5. Moser J, Hu-Lieskovan S (Apr 2020). Mechanisms of Resistance to PD-1 Checkpoint Blockade. [Review]. Drugs, 80(5), 459-465.
6. Davda J, Declerck P, Hu-Lieskovan S, Hickling T, Jacobs I, Chou J, Salek-Ardakani S, Kraynov E (April 2019). Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. [Review]. J Immunother Cancer, 7, Article: 105.
7. Nowicki T, Hu-Lieskovan S, Ribas A (Jan/Feb 2018). Mechanisms of Resistance to PD-1 and PD-L1 blockade. [Review]. Cancer J, 24(1), 47-53.
8. Sharma P, Hu-Lieskovan S, Wargo J, Ribas A (February 2017). Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. [Review]. Cell, 168(4), 707-723.
9. Hu-Lieskovan S, Ribas R (Jan/Feb 2017). New combination strategies using PD-1/ L1 checkpoint inhibitors as a backbone. [Review]. Cancer J, 23(1), 10-22.
10. Ribas A, Hu-Lieskovan S (November 2016). What does PD-L1 positive or negative tumors mean? Perspective for Clinical Correlates of Immunotherapy. [Review]. J Exp Med, 213(13), 2835-2840.
11. Robert L, Ribas A, Hu-Lieskovan S (February 2016). Combining targeted therapy with immunotherapy. Can 1 + 1 equal more than 2? [Review]. Semin Immunol, 28(1), 73-80.
12. Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A (July 2014). Combining targeted therapy with immunotherapy in BRAF mutant melanoma: promise and challenges. [Review]. J Clin Oncol, 32(21), 2248-2254.

Book Chapter

1. Piper M, Kluger H, Ruppin E, Hu-Lieskovan S (2023). Immune Resistance Mechanisms and the Road to Personalized Immunotherapy. In Am Soc Clin Oncol Educ Book.
2. McKean W, Moser J, Rimm D, Hu-Lieskovan S (2020). Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. In ASCO Educational Book 40 (2020) (pp. e275-e291).
3. Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S (Jan 2019). Mechanisms of Resistance to Immune Checkpoint Blockade: Why Doesn't Checkpoint Inhibitor Immunotherapy Work for All Patients? In ASCO Educational Book 39 (2019) (pp. 147-164).
4. Hu-Lieskovan S, Chmielowski B, Ribas A (2017). Cancer Immunotherapy. In Chmielowski B, Territo MC (Eds.), Manual of Clinical Oncology (Eighth Edition). Lippincott Williams & Wilkins.
5. Sharma S, Hu-Lieskovan S, Dubinett SM, Moon Lee J (2015). Addressing inflammation with immunotherapy. In Dubinett S (Ed.), Inflammation and Lung Cancer (Second Edition). New York: Springer.

Commentary

1. McKean W, Hu-Lieskovan S (2021). Combination Immunotherapy With IDO Inhibitors: Defining a Future Through Biomarker-Guided Patient Selection. . ASCO Daily News.

Editorial

1. Pal S, Hu-Lieskovan S, Agarwal N (Sep 2019). Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours? 20(11), 1473-1474.
2. Hu-Lieskovan S, Homet Moreno B, Ribas A (June 2018). Excluding T cells: Is β-catenin the full story? 27(6), 749-750.

Letter

1. Liu M, Wang X, Du X, Zhang Y, Ai C, Hu-Lieskovan S, Li T, Devenport M, Liu Y, Zheng P (2022). CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect. [Letter to the editor]. Signal Transduct Target Ther, 7(1), 224. (Read full article)

Video/Film/CD/Web/Podcast

1. Hu-Lieskovan S, Ribas A (2013). ASCO 2013 Highlights: Melanoma (review) [Web]. Available: Oncofacts.com.

Huntsman Cancer Institute News

• Fighting Melanoma and Other Cancers Using Immunotherapy
• Researcher Receives National Cancer Clinical Investigator Team Leadership Award
• Immunotherapy Leads the Way for Melanoma Treatment

• Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
• Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
• Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
• Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
• Phase I/II Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated Metastatic Melanoma Who Progressed On Prior BRAF/MEK Inhibitor Therapy
• Phase I/II Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated Metastatic Melanoma Who Progressed On Prior BRAF/MEK Inhibitor Therapy
• Phase I/II Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated Metastatic Melanoma Who Progressed On Prior BRAF/MEK Inhibitor Therapy
• Phase I/II Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated Metastatic Melanoma Who Progressed On Prior BRAF/MEK Inhibitor Therapy
• Phase I/II Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated Metastatic Melanoma Who Progressed On Prior BRAF/MEK Inhibitor Therapy
• Phase I/II Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated Metastatic Melanoma Who Progressed On Prior BRAF/MEK Inhibitor Therapy
• Phase I/II Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated Metastatic Melanoma Who Progressed On Prior BRAF/MEK Inhibitor Therapy
• Phase I/II Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated Metastatic Melanoma Who Progressed On Prior BRAF/MEK Inhibitor Therapy
• Phase I/II Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated Metastatic Melanoma Who Progressed On Prior BRAF/MEK Inhibitor Therapy
• Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study
• Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study
• Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study
• Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study
• Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study
• Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study
• Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study
• Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study
• A Phase I/II Study of BA3071 In Combination with Nivolumab In Patients with Advanced Solid Tumors
• A Phase I/II Study of BA3071 In Combination with Nivolumab In Patients with Advanced Solid Tumors
• A Phase I/II Study of BA3071 In Combination with Nivolumab In Patients with Advanced Solid Tumors
• A Phase I/II Study of BA3071 In Combination with Nivolumab In Patients with Advanced Solid Tumors
• A Phase I, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination with Pembrolizumab in Selected Advanced Solid Tumors
• A Phase I, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination with Pembrolizumab in Selected Advanced Solid Tumors
• A Phase I, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination with Pembrolizumab in Selected Advanced Solid Tumors
• RADVAX: Randomized Phase II Trial Of Ipilimumab And Nivolumab With Or Without Hypofractionated Radiotherapy In Patients With Metastatic Melanoma
• RADVAX: Randomized Phase II Trial Of Ipilimumab And Nivolumab With Or Without Hypofractionated Radiotherapy In Patients With Metastatic Melanoma
• RADVAX: Randomized Phase II Trial Of Ipilimumab And Nivolumab With Or Without Hypofractionated Radiotherapy In Patients With Metastatic Melanoma
• RADVAX: Randomized Phase II Trial Of Ipilimumab And Nivolumab With Or Without Hypofractionated Radiotherapy In Patients With Metastatic Melanoma
• RADVAX: Randomized Phase II Trial Of Ipilimumab And Nivolumab With Or Without Hypofractionated Radiotherapy In Patients With Metastatic Melanoma
• RADVAX: Randomized Phase II Trial Of Ipilimumab And Nivolumab With Or Without Hypofractionated Radiotherapy In Patients With Metastatic Melanoma
• Phase II/III Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator?s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
• Phase II/III Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator?s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
• Phase II/III Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator?s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
• Phase II/III Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator?s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
• A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
• NeoRelapse: Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients with Recurrent, High Risk, Resectable Melanoma
• NeoRelapse: Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients with Recurrent, High Risk, Resectable Melanoma
• NeoRelapse: Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients with Recurrent, High Risk, Resectable Melanoma
• NeoRelapse: Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients with Recurrent, High Risk, Resectable Melanoma
• NeoRelapse: Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients with Recurrent, High Risk, Resectable Melanoma
• NeoRelapse: Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients with Recurrent, High Risk, Resectable Melanoma
• Phase I/II, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer
• Phase I/II, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer
• Phase I/II, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer
• Phase I/II, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer
• Randomized Phase II Study of ATR Inhibition in Advanced PD-(L)1-Refractory Merkel Cell Carcinoma: The MATRiX Trial (NCT TBD)
• Randomized Phase II Study of ATR Inhibition in Advanced PD-(L)1-Refractory Merkel Cell Carcinoma: The MATRiX Trial (NCT TBD)
• Randomized, Open-Label Phase III Study in Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma Comparing the Combination of Naporafenib + Trametinib to Physician?s Choice of Therapy (Dacarbazine, Temozolomide or Trametinib Monotherapy) with A Dose Optimization Lead-In [SEACRAFT-2]